They say you can't know where you're going, if you don't know where you've been... BioWorld Biotech Super Book — coverage like never before! We've taken one of our most requested resources — The BioWorld State of the Industry Report — and enhanced it! The brand new 475-page report includes the deals, the projections, the R&D, the latest trends, the industry analysis, and the top drugs that surrounded our year... and shaped the future. From the bench to Wall Street to DC to Europe — The BioWorld
State of the Industry Report | Wednesday, June 9, 2010
BioWorld ranked the underwriters of 2008’s public offerings, both initial and follow-on, in two basic ways. First, BioWorld ranked the underwriters based on the total amount of gross proceeds raised in both initial and follow-on public offerings combined. If an underwriting firm acted as the sole placement agent for an institutional offering, then that firm was credited as “lead” underwriter. If more than one firm acted as a lead underwriter, then both were credited as such for the purpose of
State of the Industry Report | Sunday, February 28, 2010
Staff Writer Although the biotech industry spent much of 2007 insulated from broader economic woes, the bone-chilling 2008 recession left many companies stranded amid frozen capital markets, shivering without financial cover. In 2007, sliding biotech stock prices translated to less money raised through follow-on offerings, but a significant uptick in private company financings and a huge jump in alternative financings such as convertible note deals helped the industry come out ahead for the
By Trista Morrison | State of the Industry Report | Sunday, February 28, 2010
Staff Writer Dealmaking takes on new challenges in tough economic times, but despite those hurdles some notable mergers and acquisitions emerged in 2008 in the biopharmaceutical industry, some of which stood out for their creativity or value to pharmaceutical firms. While much of the industry’s M&A activity in 2008 was driven by acquisitions by big pharma, other deals were the result of European and Japanese firms courting U.S.-based firms. And in several instances, parties resorted to reverse
By Catherine Hollingsworth | State of the Industry Report | Sunday, February 28, 2010
Science Editor Stem cell research promises to be a highlight of 2009, with Geron Corp. receiving permission for the first clinical trial of human embryonic stem cells within a week of President Obama’s inauguration – a bit of timing that seemed unlikely to be coincidence to many observers. Embryonic stem cell research also is likely to profit next year from an improved understanding of how the embryonic stem cells from mice and humans map onto each other at different stages of development. And
By Anette Breindl | State of the Industry Report | Sunday, February 28, 2010
BioWorld Correspondent With its need for constant cash infusions, biotech has always lived close to the edge. Now, as the financial crisis seeps throughout the economy, Europe’s development stage companies are finding it virtually impossible to raise money. The initial public offering window is closed, bolted and boarded up, venture capital has evaporated and quoted companies have depressed share prices. London Alternative Investment Market’s all share index has fallen by 50 percent since
By Nuala Moran | State of the Industry Report | Sunday, February 28, 2010
Washington Editor With the presidential election taking center stage and lawmakers’ attention being shifted to the global economic crisis, legislation affecting the biotechnology industry had little chance of moving through Congress in 2008. Nonetheless, with President Obama’s focus on health care, many of those stalled bills are expected to make progress or succeed in 2009, including follow-on biologics, patent reform and another overhaul of the FDA. However, some health care legislation
By Donna Young | State of the Industry Report | Sunday, February 28, 2010
Assistant Managing Editor In a year of collapsing financing institutions and financial panic that sent U.S. stock indexes plunging to record lows, investing in (and working on) Wall Street was not for the faint of heart. Even biotech, an industry that’s been insulated at least partially from larger macroeconomic issues, couldn’t escape the market’s spectacular downward trajectory in 2008, with the AMEX Biotech Index slipping 17.7 percent compared to 2007 and the Nasdaq Biotech Index falling 12
By Jennifer Boggs | State of the Industry Report | Sunday, February 28, 2010
Assistant Managing Editor After several steady – if perhaps not stellar – years for the biotech industry, 2008 brought with it gale-force winds that ripped through the credit and capital markets, leaving in its wake a rabble of companies facing crumbling valuations and shrinking bank balances, with limited financing options in sight. Economic troubles pervaded the global economy throughout 2008, eventually causing the National Bureau of Economic Research to declare an official recession in the
By Jennifer Boggs | State of the Industry Report | Sunday, February 28, 2010
Managing Editor A saying generally attributed to the Chinese long before they became involved in biotech, or even nontraditional pharmaceuticals, went: May you live in interesting times. These times are definitely interesting for everyone, especially drugmakers. Biotech has actually fared better than many markets – aren’t you glad you’re not in banking? Still, faced with markets that keep redefining what “the bottom” means, exits that quickly closed, and a new administration in Washington
By Glen Harris | State of the Industry Report | Sunday, February 28, 2010
Biotech Co.* (Country; Symbol) Pharma Co. (Country) Product Terms/Details (Date) FIRST QUARTER Acambis plc (UK; LSE:ACM) Sanofi Pasteur (France) Agreement to license a single dose vaccine, ChimeriVax, for Japanese encephalitis Deal could be worth nearly $40M; Sanofi Pasteur gains marketing, distribution and certain manufacturing rights worldwide, excluding India and the Indian subcontinent, and the U.S., for which Sanofi Pasteur has an option (2/14) Affectis Pharmaceuticals AG* (Germany
State of the Industry Report | Thursday, February 25, 2010
Company* (Country; Symbol) Company (Country) Type/Product Area Terms/Details (Date) FIRST QUARTER Anavex Life Sciences Corp.* Alexandre Vamvakides Agreement for rights to a portfolio of three patents and one patent application covering drug candidates targeting neurological diseases and cancer Anavex agreed to pay for the development of the compounds by spending not less than $200,000 per year (1/31) Debiopharm Group* (Switzerland) Kirin Brewery Co. Ltd. (Japan) Exclusive agreement for
State of the Industry Report | Monday, January 18, 2010
Company* (Country; Symbol) Company* (Country; Symbol) Product Terms/Details (Date) FIRST QUARTER Adventrx Pharmaceuticals Inc. (AMEX:ANX) Pharmatek Laboratories Inc.* Manufacturing agreement for Adventrx's ANX-201 (Thiovir) capsules for clinical studies Phase I/II combination trials in HIV patients are expected to begin in the third quarter (3/20) Aldagen Inc.* StemCell Technologies Inc.* Worldwide distribution agreement under which StemCell will distribute Aldagen's Aldecount product
State of the Industry Report | Monday, January 18, 2010
Biotech Co.* (Country; Symbol) Pharma Co. (Country) Change from original agreement Terms/Details (Date) I. MODIFIED AGREEMENTS FIRST QUARTER Adherex Technologies Inc. (AMEX:ADX) GlaxoSmithKline plc (UK) Adherex acquired all rights to the cancer agent eniluracil, which was the subject of a July 2005 option agreement GSK had options to reacquire eniluracil at various points of development; Adherex paid $1M to purchase the remaining options (1/18) ChemDiv Inc.* Merck KGaA (Germany) Renewed
State of the Industry Report | Monday, January 4, 2010
Company* (Symbol) Product Description Indication Action/Date Aastrom Biosciences Inc. (ASTM) Tissue Repair Cells Consist of a mixture of stem and progenitor cell populations, produced from a small amount of bone marrow taken from the patient Dilated cardiomyopathy FDA granted orphan drug designation (2/1) Active Biotech AB (Sweden; SSE:ACTI) Anyara Antibody linked to a toxin designed to stimulate immune system to target and kill cancer cells Renal cancer Was granted orphan drug status by
State of the Industry Report | Tuesday, October 27, 2009
Company* (Symbol) Product Description Indication Action/Date Abbott Laboratories (NYSE:ABT) Humira (FDA-approved) Adalimumab; fully human antibody designed to block TNF-alpha Crohn's disease The EMEA's CMPH recommended approval (4/27); received marketing authorization from the European Commission (6/7) Abbott Laboratories (NYSE:ABT) Humira (FDA-approved) Adalimumab; fully human monoclonal antibody Moderate to severe chronic plaque psoriasis Submitted an sBLA and a Type II Variation to the
State of the Industry Report | Thursday, October 22, 2009
Company Symbol Close 12/31 YTD Aastrom Biosci ASTM 0.5 -3.85 Acadia Pharma ACAD 0.9 -91.87 Accelrys ACCL 4.36 -42.10 Access Pharma ACCP 0.99 -69.54 Achillion ACHN 0.68 -86.37 Acorda Therapeutics ACOR 20.51 -6.60 Acusphere ACUS 0.07 -89.23 AEterna Zentaris AEZS 0.49 -68.18 Affymax AFFY 9.99 -55.32 Affymetrix AFFX 2.99 -87.08 Albany Molecular AMRI 9.74 -32.27 Alexion Pharma ALXN 36.19 -3.54 Alexza Pharma ALXA 3.17 -60.82 Alkermes ALKS 10.65